EpicentRx Announces Presentations Focusing on RRx-001 Inhibition of the NLRP3 Inflammasome at Two Upcoming Scientific Conferences
/PRNewswire/ -- EpicentRx, a late clinical stage biopharmaceutical company with novel therapies to target cancer and inflammatory diseases, announced it will...
Source: prnewswire.com